A panel-agnostic strategy ‘HIPPo’ improves diagnostic efficiency in the UK Genomic Medicine Service
A panel-agnostic strategy ‘HIPPo’ improves diagnostic efficiency in the UK Genomic Medicine Service
Genome sequencing is available as a clinical test in the UK through the Genomic Medicine Service (GMS). The GMS analytical strategy predominantly filters genome data on pre-selected gene panels. Whilst this reduces variants requiring assessment by reporting laboratories, pathogenic variants outside applied panels may be missed, and variants in genes without established disease-gene relationships are largely ignored. This study compares analysis of a research exome to a GMS clinical genome for the same patients. For the research exome, we applied a panel-agnostic approach filtering for variants with High Pathogenic Potential (HiPPo) using ClinVar, allele frequency, and in silico prediction tools. We then restricted HiPPo variants to Gene Curation Coalition (GenCC) dis-ease genes. These results were compared with the GMS genome panel-based approach. 24 participants from 8 families underwent parallel research exome and GMS genome sequencing. Exome HiPPo analysis identified a similar number of variants as the GMS panel-based approach. GMS genome analysis returned 2 pathogenic variants and 1 de novo variant. Exome HiPPo analysis re-turned the same variants plus an additional pathogenic variant and 3 further de novo variants in novel genes, where case series are underway. When HiPPo was restricted to GenCC disease genes, statistically fewer variants required assessment to identify more pathogenic variants than reported by the GMS, giving a diagnostic rate per variant assessed of 20% for HiPPo versus 3% for the GMS. With UK plans to sequence 5 million genomes, strategies are needed to optimise genome analysis beyond gene panels whilst minimising the burden of variants requiring clinical assessment.
Seaby, Eleanor G.
ec948f42-007c-4bd8-9dff-bb86278bf03f
Simon Thomas, N.
2736b8b1-d10e-484a-bda8-8b761344a93e
Hunt, David
a744ddd0-df7d-44f7-bb9c-c91e188c3bb3
Baralle, Diana
faac16e5-7928-4801-9811-8b3a9ea4bb91
Rehm, Heidi L.
0e4087b7-519d-4b95-84ac-412d1c0173d1
O'Donnell-Luria, Anne
cb827331-5ea7-4877-9074-a0efbf1907e1
Ennis, Sarah
7b57f188-9d91-4beb-b217-09856146f1e9
Seaby, Eleanor G.
ec948f42-007c-4bd8-9dff-bb86278bf03f
Simon Thomas, N.
2736b8b1-d10e-484a-bda8-8b761344a93e
Hunt, David
a744ddd0-df7d-44f7-bb9c-c91e188c3bb3
Baralle, Diana
faac16e5-7928-4801-9811-8b3a9ea4bb91
Rehm, Heidi L.
0e4087b7-519d-4b95-84ac-412d1c0173d1
O'Donnell-Luria, Anne
cb827331-5ea7-4877-9074-a0efbf1907e1
Ennis, Sarah
7b57f188-9d91-4beb-b217-09856146f1e9
Seaby, Eleanor G., Simon Thomas, N., Hunt, David, Baralle, Diana, Rehm, Heidi L., O'Donnell-Luria, Anne and Ennis, Sarah
(2023)
A panel-agnostic strategy ‘HIPPo’ improves diagnostic efficiency in the UK Genomic Medicine Service.
Healthcare.
(In Press)
Abstract
Genome sequencing is available as a clinical test in the UK through the Genomic Medicine Service (GMS). The GMS analytical strategy predominantly filters genome data on pre-selected gene panels. Whilst this reduces variants requiring assessment by reporting laboratories, pathogenic variants outside applied panels may be missed, and variants in genes without established disease-gene relationships are largely ignored. This study compares analysis of a research exome to a GMS clinical genome for the same patients. For the research exome, we applied a panel-agnostic approach filtering for variants with High Pathogenic Potential (HiPPo) using ClinVar, allele frequency, and in silico prediction tools. We then restricted HiPPo variants to Gene Curation Coalition (GenCC) dis-ease genes. These results were compared with the GMS genome panel-based approach. 24 participants from 8 families underwent parallel research exome and GMS genome sequencing. Exome HiPPo analysis identified a similar number of variants as the GMS panel-based approach. GMS genome analysis returned 2 pathogenic variants and 1 de novo variant. Exome HiPPo analysis re-turned the same variants plus an additional pathogenic variant and 3 further de novo variants in novel genes, where case series are underway. When HiPPo was restricted to GenCC disease genes, statistically fewer variants required assessment to identify more pathogenic variants than reported by the GMS, giving a diagnostic rate per variant assessed of 20% for HiPPo versus 3% for the GMS. With UK plans to sequence 5 million genomes, strategies are needed to optimise genome analysis beyond gene panels whilst minimising the burden of variants requiring clinical assessment.
Text
healthcare-2730148_EGS_clean
- Accepted Manuscript
More information
Accepted/In Press date: 13 December 2023
Identifiers
Local EPrints ID: 485707
URI: http://eprints.soton.ac.uk/id/eprint/485707
ISSN: 2227-9032
PURE UUID: 52155c65-3b2d-4c7b-96ef-34cc43f2154f
Catalogue record
Date deposited: 15 Dec 2023 17:32
Last modified: 13 Aug 2024 04:01
Export record
Contributors
Author:
Eleanor G. Seaby
Author:
N. Simon Thomas
Author:
David Hunt
Author:
Heidi L. Rehm
Author:
Anne O'Donnell-Luria
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics